^
Association details:
Biomarker:NOTCH3 mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

P14.13 - Notch Family Gene Mutations Predict Clinical Benefit from Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer

Published date:
01/12/2021
Excerpt:
250 (17.36%) of the NSCLC patients had Notch mutation. In the ICI-treated cohort, patients with Notch mutation had longer OS (median OS, 22.00 vs 11.15 months...NSCLC patients with Notch mutation especially those with more Notch mutations get longer OS and better response in ICI treatment, making Notch mutation a positive predictive biomarker.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes

Published date:
08/08/2020
Excerpt:
...we confirmed the relationship between the NOTCHmut/HRmut signature and longer progression-free survival (PFS) in ICI-treated patients (multivariate Cox: HR 0.51, 95% CI 0.34 to 0.76, p=0.001). The NOTCHmut/HRmut genomic predictor was also associated with longer survival (log-rank p=0.008), despite patients whose tumors carried the NOTCHmut/HRmut signature had higher metastatic burden as compared with their negative counterpart.
DOI:
10.1136/jitc-2020-000946